OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OVID
Ovid Therapeutics Inc.
There isn't enough reported data to score OVID yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OVID Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OVID's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OVID PE Valuation
OVID has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OVID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OVID's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over OVID on earnings quality, reporting a profit while its opponent remains loss making.
OVID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | +$0.33 |
| Q2 2026 | -$0.23 | +$0.29 |
| Q1 2026 | -$0.21 | +$0.13 |
| Q4 2025 | -$0.23 | +$0.14 |
| Q3 2025 | -$0.49 | -$0.03 |
| Q2 2025 | -$0.52 | -$0.10 |
| Q1 2025 | -$0.34 | +$0.38 |
| Q4 2024 | -$0.37 | +$0.37 |
OVID is still losing money, but far less than before: $0.16 per share over the past year, against $1.46 at its worst in mid-2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OVID on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OVID on profitability, with a higher operating margin.
OVID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $733K | -88% |
| Q4 2025 | $718K | +845% |
| Q3 2025 | $132K | -24% |
| Q2 2025 | $6.3M | +3611% |
| Q1 2025 | $130K | -12% |
| Q4 2024 | $76K | -46% |
| Q3 2024 | $173K | +59% |
| Q2 2024 | $169K | +125% |
OVID's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2142% | -2061 points |
| Q4 2025 | -1712% | +12396 points |
| Q3 2025 | -9487% | -1842 points |
| Q2 2025 | -81% | +12059 points |
| Q1 2025 | -9654% | +2114 points |
| Q4 2024 | -14108% | -1260 points |
| Q3 2024 | -7645% | +3393 points |
| Q2 2024 | -12140% | +6756 points |
OVID's operating margin was −2142% last quarter, up 7512 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OVID on cash generation, producing positive trailing cash flow while its opponent burns cash.
OVID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$3M |
| Q2 2026 | -$17.6M | -$12.8M |
| Q1 2026 | -$13.9M | -$3.6M |
| Q4 2025 | -$10.4M | -$378K |
| Q3 2025 | -$12.9M | +$2.1M |
| Q2 2025 | -$4.8M | +$9.5M |
| Q1 2025 | -$10.3M | +$6.4M |
| Q4 2024 | -$10M | +$1.9M |
OVID has burned cash in almost every quarter: −$58M over the past year, against −$38M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over OVID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OVID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -6.6M shares |
| 1 year | +165% | +118M shares |
| 3 years | +167% | +118M shares |
| 5 years | +178% | +121M shares |
| Available history | +245% | +134M shares |
OVID has 189M diluted shares, up 165% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OVID Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.5x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.7x | Net Cash |
| Q1 2021 | -2.0x | Net Cash |
OVID has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OVID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.0 | Neutral |
| Stochastic | 62.2 | Neutral |
OVID's weekly RSI is 52 (neutral) and its Stochastic is 62 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OVID PE vs Healthcare Sector
OVID has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
OVID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 4.5% above |
| 20 week MA | $2.55 | 0% above |
| 50 week MA | $2.28 | 12% above |
| 100 week MA | $1.53 | 67% above |
| 200 week MA | $2.11 | 21% above |
OVID's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OVID on returns for 2026, with the stronger performance.
OVID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.61 | $2.61 | -43% |
| 2021 | $2.61 | $3.39 | +30% |
| 2022 | $3.39 | $1.70 | -50% |
| 2023 | $1.70 | $3.22 | +89% |
| 2024 | $3.22 | $0.97 | -70% |
| 2025 | $0.97 | $1.78 | +84% |
| 2026 YTD | $1.78 | $2.55 | +43% |
OVID is up 43% so far in 2026, after finishing lower in three of the previous six years.